XERS — Xeris Biopharma Holdings Income Statement
0.000.00%
Last trade - 00:00
- $259.44m
- $377.92m
- $163.91m
- 46
- 49
- 61
- 51
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.72 | 20.4 | 49.6 | 110 | 164 |
Cost of Revenue | |||||
Gross Profit | 1.12 | 11.1 | 36.3 | 87.6 | 135 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 125 | 105 | 165 | 193 | 211 |
Operating Profit | -122 | -84.3 | -115 | -83.1 | -46.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -126 | -91.3 | -123 | -96.1 | -63.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -126 | -91.1 | -123 | -94.7 | -62.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -126 | -91.1 | -123 | -94.7 | -62.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -126 | -91.1 | -123 | -94.7 | -62.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.81 | -2.13 | -1.44 | -0.644 | -0.439 |